Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Psychedelics Business

News
Psychedelics Briefs: MindMed, Numinus Wellness
01/21/2022
MindMed has accepted its first patient into a study, while a research project for Numinus Wellness has cleared several regulatory hurdles.
MindMed has accepted its first patient into a study, while a research project for Numinus Wellness has cleared several regulatory hurdles.
MindMed has accepted its first...
01/21/2022
Behavioral Healthcare Executive
News
Psychedelics Briefs: Numinus, Pacific Neuroscience Institute, Delix
01/14/2022
Numinus Wellness and Pacific Neuroscience Institute have announced developments around clinical trials, while Delix Therapeutics has secured new funding to expand its operations.
Numinus Wellness and Pacific Neuroscience Institute have announced developments around clinical trials, while Delix Therapeutics has secured new funding to expand its operations.
Numinus Wellness and Pacific...
01/14/2022
Behavioral Healthcare Executive
News
Amendment Allows Canadian Physicians to Request Access to Psychedelic Treatments
01/11/2022
Health Canada announced it has amended its Special Access Program to allow qualified physicians to request access to psychedelic treatments for serious, treatment-resistant or life-threatening health conditions when other therapies have...
Health Canada announced it has amended its Special Access Program to allow qualified physicians to request access to psychedelic treatments for serious, treatment-resistant or life-threatening health conditions when other therapies have...
Health Canada announced it has...
01/11/2022
Psych Congress Network
BHE Psychedelics Podcast
BHE Podcast
BHE Psychedelics Podcast, Episode 002 – Brian Mears, Alleviant Health Centers founder, president and CEO
01/07/2022
Brian Mears, Alleviant Health Centers founder, president and CEO, discusses best practices for behavioral healthcare providers who are interested in adding a ketamine-assisted treatment option to their service offerings.
Brian Mears, Alleviant Health Centers founder, president and CEO, discusses best practices for behavioral healthcare providers who are interested in adding a ketamine-assisted treatment option to their service offerings.
Brian Mears, Alleviant Health...
01/07/2022
Behavioral Healthcare Executive
News
Psychedelics Briefs: Mindset Pharma, Otsuka Pharmaceutical, Novamind, Foundations for Change
01/05/2022
Otsuka Pharmaceutical’s McQuade Center for Strategic Research and Development (MSRD) has announced a collaboration with Mindset Pharma to support the development of psychedelic medicines.
Otsuka Pharmaceutical’s McQuade Center for Strategic Research and Development (MSRD) has announced a collaboration with Mindset Pharma to support the development of psychedelic medicines.
Otsuka Pharmaceutical’s McQuade...
01/05/2022
Behavioral Healthcare Executive
News
TCIV: Holistic, User-Friendly Approach Will Fuel Digital Marketing Success
12/11/2021
In a wide-ranging industry forecast, Dreamscape Marketing President and CEO Dan Gemp shared best practices for behavioral healthcare providers’ websites, social media, and other marketing channels.
In a wide-ranging industry forecast, Dreamscape Marketing President and CEO Dan Gemp shared best practices for behavioral healthcare providers’ websites, social media, and other marketing channels.
In a wide-ranging industry...
12/11/2021
Behavioral Healthcare Executive
News
Psychedelics Briefs: Cybin, Novamind, Revitalist
12/09/2021
Cybin has received approval for a Phase 2 trial to evaluate psychedelic-assisted psychotherapy with psilocybin for frontline clinicians experiencing COVID-related distress, Novamind has opened an addiction treatment clinic in Utah, and...
Cybin has received approval for a Phase 2 trial to evaluate psychedelic-assisted psychotherapy with psilocybin for frontline clinicians experiencing COVID-related distress, Novamind has opened an addiction treatment clinic in Utah, and...
Cybin has received approval for...
12/09/2021
Behavioral Healthcare Executive
News
Psychedelics Briefs: Cybin, Lenox Hill Hospital, Delic, Ketamine Wellness Clinics
11/25/2021
Cybin has awarded a grant to fund the launch of a psychedelic medicine clinical site at Lenox Hill Hospital in New York, while Delic announced the launch of a family support program at its Ketamine Wellness Centers.
Cybin has awarded a grant to fund the launch of a psychedelic medicine clinical site at Lenox Hill Hospital in New York, while Delic announced the launch of a family support program at its Ketamine Wellness Centers.
Cybin has awarded a grant to...
11/25/2021
Behavioral Healthcare Executive
BHE Psychedelics Podcast
BHE Podcast
BHE Psychedelics Podcast, Episode 001 – Payton Nyquvest, CEO and founder of Numinus Wellness
11/24/2021
Numinus Wellness CEO and founder Payton Nyquvest discusses the emergence of psychedelics, how psychedelic-assisted psychotherapy integrates with existing treatment modalities, as well as investors' interest and payers' views on psychedelics.
Numinus Wellness CEO and founder Payton Nyquvest discusses the emergence of psychedelics, how psychedelic-assisted psychotherapy integrates with existing treatment modalities, as well as investors' interest and payers' views on psychedelics.
Numinus Wellness CEO and founder...
11/24/2021
Behavioral Healthcare Executive
News
Novamind Secures Coverage from 4 Insurers for IV Ketamine Treatment
11/11/2021
Novamind announced it has obtained approval for direct billing of IV ketamine for treatment-resistant depression from Blue Cross Blue Shield, University of Utah, PEHP Health & Benefits, and MBA Benefit Administrators.
Novamind announced it has obtained approval for direct billing of IV ketamine for treatment-resistant depression from Blue Cross Blue Shield, University of Utah, PEHP Health & Benefits, and MBA Benefit Administrators.
Novamind announced it has...
11/11/2021
Behavioral Healthcare Executive

Advertisement

Stay in the Know

Behavioral Healthcare Executive Newsletter

Popular Articles

News
Shire explores use of Vyvanse as adjunctive treatment for MDD
11/04/2010
Philadelphia, PA —Shire plc, the global specialty biopharmaceutical company, today announced results from a Phase 2 signal finding study of Vyvanse
Philadelphia, PA —Shire plc, the global specialty biopharmaceutical company, today announced results from a Phase 2 signal finding study of Vyvanse
Philadelphia, PA —Shire plc, the...
11/04/2010
Behavioral Healthcare Executive
How to handle the holidays at your treatment center
12/12/2016
Beyond the clinical scope, treatment center operators must manage everyday matters such as staffing levels, meals, visitation schedules and policies as the 2016 holidays approach.
Beyond the clinical scope, treatment center operators must manage everyday matters such as staffing levels, meals, visitation schedules and policies as the 2016 holidays approach.
Beyond the clinical scope,...
12/12/2016
Behavioral Healthcare Executive
News
Medicaid expenditures for autism on rapid rise
10/26/2010
Washington, DC — Autism was described as early as 1940, but a marked increase in the prevalence for the broader class of autism spectrum disorders
Washington, DC — Autism was described as early as 1940, but a marked increase in the prevalence for the broader class of autism spectrum disorders
Washington, DC — Autism was...
10/26/2010
Behavioral Healthcare Executive
Task force arms local officials in opioid crisis
11/21/2016
A report issued by the City-County National Task Force on the Opioid Epidemic provides local government and law enforcement officials with strategies for taking action to address the opioid crisis at the community level.
A report issued by the City-County National Task Force on the Opioid Epidemic provides local government and law enforcement officials with strategies for taking action to address the opioid crisis at the community level.
A report issued by the...
11/21/2016
Behavioral Healthcare Executive
News
Court-ordered outpatient treatment reduces recidivism
10/13/2010
Arlington, VA — Court-ordered outpatient treatment—often called “assisted outpatient treatment” or “AOT—is effective in reducing the arrest rate for
Arlington, VA — Court-ordered outpatient treatment—often called “assisted outpatient treatment” or “AOT—is effective in reducing the arrest rate for
Arlington, VA — Court-ordered...
10/13/2010
Behavioral Healthcare Executive

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement